Related Experiment Video

Updated: Jul 17, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Managing dermatologic toxicities of epidermal growth factor receptor inhibitors

Lillian S Chou1, Jody Garey, Karen Oishi

  • 1University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Clinical Lung Cancer
|January 24, 2007
PubMed

Insights

Rash, a common side effect of epidermal growth factor receptor (EGFR) inhibitors, may predict treatment response in non-small-cell lung cancer. Effective rash management is crucial for patients receiving EGFR-targeted therapies.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) signaling is implicated in non-small-cell lung cancer (NSCLC) progression.
  • EGFR inhibitors demonstrate significant efficacy in specific NSCLC patient subgroups.
  • Adverse events, particularly rash, associated with EGFR inhibitors have been investigated as potential response biomarkers.

Purpose of the Study:

  • To explore the correlation between rash and therapeutic outcomes in patients treated with EGFR inhibitors for NSCLC.
  • To highlight the clinical imperative for effective rash management strategies to optimize anti-EGFR therapy.
  • To identify the need for evidence-based guidelines and further clinical trials for managing EGFR inhibitor-induced rash.

Main Methods:

  • Review of clinical trials and observational studies evaluating EGFR inhibitors in NSCLC.
  • Analysis of reported correlations between rash occurrence/severity and treatment response/survival.
  • Examination of the current challenges in rash etiology, grading, and management.

Main Results:

  • Several studies report a positive association between rash and treatment response, as well as survival, in NSCLC patients receiving anti-EGFR therapy.
  • Lack of standardized rash management protocols and grading scales hinders consistent clinical practice.
  • Preliminary data from a prospective algorithm evaluation at M. D. Anderson Cancer Center show positive results.

Conclusions:

  • Rash may serve as a predictive marker for anti-EGFR therapy efficacy in NSCLC.
  • Systematic, evidence-based guidelines for managing EGFR inhibitor-induced rash are currently lacking.
  • Further prospective clinical trials are essential to establish optimal rash management strategies and improve patient outcomes.

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular cells,...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...